Apoptosis and CD95 ligand in immune privileged sites

International Reviews of Immunology

Volumn 18, Issue 5-6, 1999, Pages 547-562

  Bellgrau, Donald ^a   Duke, Richard C ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Antigens; Potential pathogens; Thymus; Xenograft

Indexed keywords

EID: 0033384720     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.3109/08830189909088498     Document Type: Review

References (74)

1. N. Hozumi and S. Tonegawa. Evidence for somatic rearrangement of immunoglobulin gens coding for variable and constant regions. Proc. of Natl. Acad. of Sci., 1976,73: 3628-3632.
2. J.W. Kappler, N Roehm and P. Marrack. T cell tolerance by clonal elimination in the thymus. Cell, 1987, 49: 273-280.
3. J.F. Miller and W.R. Heath Self-ignorance in the peripheral T-cell pool. Immunol. Rev., 1993, 133: 131-150
4. R.E. Billingham, L. Brent and P.B. Medawar. Actively acquired tolerance of foreign cells. Nature, 1953, 172: 603-607.
5. K.S. Tung. Mechanism of self tolerance and events leading to autoimmune disease and autoantibody response. Clin. Immunol. Immunopathol., 1994, 73: p. 275-282.
6. C.F. Barker and R.E. Billingham. Immunologically privileged sites. Adv. in Immunol., 1977, 25: 1-54.
7. G. Qvist and John Hunter, William Heinemann, London, 1981, pp. 1728-1793.
8. B.P. Setchell. The testis and tissue transplantation: historical aspects. J. of Reproductive Immunology, 1990, 18: 1-8.
9. C.B. Jorgensen and J. Hunter, A.A Berthold and origins of endocrinology. Acta Hist. Scient. Natural Medic., 1971,24: 17-54.
10. C.E. Brown-Sequard. Du role physiologique et therapeuticue d'un suc extrait de testicules d'animaux d'apres nombre observes chez l'homme. Archives de physiologie normale a pathologique 5th series, 1889, Vol. 1: pp. 739-746.
11. R. Gosden. The gland grafters in Cheating Time; Science, Sex and Aging. W.H. Freeman and Company, Basinstoke, England, 1996, pp. 212-220.
12. G.F, Lydston. Transplantation of testicle from the dead to the living body: suggestiveness of results in their relation to the etiology and treatment of psoriasis, carcnoma etc. N. Y. Med. J., 1914, 100: 67-69.
13. J.C. Van Dooremaal. Albrecht von graefes. Arch. Opthalmol., 1873, 19: 359-362.
14. F.W. Zahn. Uber das Schicksal der in den Organismus implantiren Gewebe. Virchow's Arch. Pathol. Anat. Physiol., 1884,95: 369-387.
15. H.S.N. Greene. Conception of tumor autonomy based on transplantation studies. Cancer Res., 1951, 11; 899-903.
16. E. Ebeling. Experimentelle Gehirntumoren fel Maeusen. Z.F. Krebsforsch, 1914, 14: 151-156.
17. Y. Shirai. On the transplantation of the rat sarcoma in adult heterogenous animals. Jpn. Med. World, 1921, 2: 14-17.
18. J.B. Murphy, and E. Sturm. Homoplastic and heteroplastic tumor grafts in the brain. J. Am. M. Ass., 1922, 38: 2159-2169.
19. B.R. Lutz, G.P. Fulton, D.I. Patt and A.H. Handler. Cancer Res., 1950, 10:231-232.
20. H.M. Lemon, B.R. Lutz, R. Pope, L. Parsons, A.H. Handler and D.I. Patt, Science, 1952, 115: 461-465.
21. A.H. Handler and D. Shepiro. In "The Golden Hamster; its Biology and Use in Medical Research". Iowa State Univ. Press, Iowa City , 1968, pp. 195-202.
22. A.F. Nakhooda, A.A. Like, C.I. Chappel, C.-N. Wei and E.B. Marliss. The spontaneously diabetic Wistar (the "BB" rat). Diabetologia, 1978, 14 199-207.
23. A. Naji, W.K. Silvers, D. Bellgrau and C.F. Barker. Spontaneous diabetes in rats: destruction of islets is prevented by immunological tolerance. Science, 1981, 213: 1390-1392
24. D E Sutherland, R. Sibley, X.Z. Xu, A. Michael, A.M. Sirkanta, F. Taub. J. Najarian and F.C. Goetz. Twin-to-twin pancreas transplantation: Reversal and reenactment of the pathogenesis of type I diabetes. Transplant. Assoc. American Physician, 1984,97: 80-87.
25. B. Bobzien, Y. Yasunami, M. Majercik, P.E. Lacy and J.M. Davie. Intratesticular transplants of islet xenografts (rat to mouse). Diabetes, 1983, 32(3): 213-216.
26. H.P. Selawry and K. Whittington. Extended allograft survival of islets grafted into intra-abdominally placed testis. Diabetes, 1984, 33(4): 405-406
27. H.P. Selawry, R. Fojaco, K Whittington Extended survival of MHC-compatible islet grafts from diabetes-resistant donors in spontaneously diabetic BB W rat. Diabetes, 1987,36: 1061-1067.
28. M.I. Arbuzova, A.V. Kulikow and T.M. Tretiak. Levels of immunoreactive insulin in the pancreas and allograft to the anterior chamber of the eye in experimental diabetes. Problemy Endokrinologii., 1991, 37(1): 42-44.
29. W.J. Tze and J. Tai. Successful interacerebral allotransplantation of purified pancreatic endocrine cells in diabetic rat. Diabetes, 1983, 32(12): 1185-1187.
30. H.J. Kaplan and T.R Stevens. A reconsideration of immunological privilege within the anterior chamber of the eye. Transplantation, 1975, 19(4): 203-209.
31. J.R. Head, W.P. Neaves and R.E. Billingham. Reconsideration of the lymphatic drainage of the rat testis. Transplantation, 1983, 35: 91-95.
32. H.P. Selawry and D F, Cameron. Sertoli cell-enriched fractions in successful islet cell transplantation. Cell Transplantation, 1993, 2(2): 123-129.
33. D. Bellgrau and H. Selawry. Cyclosporine-induced tolerance to intratesticular islet xenografts. Transplantation, 1990, 50:654-657.
34. R.C. Duke Self-recognition by T cells. I. Bystander killing of target cells bearing syngeneic MHC antigens. J. Exp. Med., 1989, 170: 59-71.
35. E. Rouvier, M.F. Luciani and P. Golstein. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J. Exp. Med., 1993, 177: 195-200.
36. P.L. Cohen. and R.A. Eisenberg. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu, Rev. Irnmunol, 1991, 9: 243-269.
37. R. Watanabe-Fukunaga, C.I. Brannan, N.G. Copeland, N.A. Jenkins and S. Nagata. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature, 1992, 356: 314-317.
38. R. Watanabe-Fukunaga, C.I. Branna, N. Itoh, S. Yonehara, N.G. Copeland, N.A. Jenkins and S. Nagata, The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol., 1992, 148: 1274-1279.
39. F. Ramsdall. Gld/gld mice are unable to express a functional ligand for Fas. Eur. J. of Immunol, 1994, 24: 928-933.
40. J.H. Russell and R Wang. Autoimmune gld mutation uncouples suicide and cytokine, proliferation pathways in activated, mature T cells Eur. J. Immunol., 1993, 23: 2379-2382.
41. T. Suda, T. Takahashi, P. Golstien and S. Nagata Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993, 75: 1169-1178.
42. T. Suda and S. Nagata. Purification and chracterization of the Fas-ligand that induces apoptosis. J. Exp. Med., 1994, 179: 873-879
43. M.C. Peitsch and J. Tschopp. Comparative molecular modeling of the Fas-ligand and other members of the TNF family. Molecular Immunology, 1993, 32: 761-772.
44. L Hao and K.J. Lafferty, A.C. Allison and E.M. Eugui RS-61443 allows islet allografting and specific tolerance induction in mice. Transplantation Pros., 1990, 20, 876-879.
45. D. Bellgrau, D. Gold. H. Selawry, J. Moore, A. Franzusoff and R.C. Duke. A role for CD95 ligand in presenting graft rejection Nature, 1995, 377: 630-632.
46. D.M. de Kretser, R.M Sharpe and I.A Swanston. Alterations in steroidogenesis and human chorionic gonadotropin binding in the cryptorchid rat testis. Endocrinology, 1979, 105(1): 135-138.
47. W.B. Neaves and R.E. Billingham. Transplantation of the testis Transplantation, 1979, 28(3): 163-165
48. J.R. Head, W.B. Neaves and R.E. Billingham. Immune privilege in the testis. I. Basic parameters of allograft survival. Transplantation, 1983, 36(4): 423-431
49. M.B. Statter, R.P. Foglia, D.E. Parks and P.K. Donahoe. Fetal and Postnatal testis shows immunoprivilege as donor tissue. The Journal of Urology, 1988, 139: 204-210.
50. H.P. Selwary. Islet transplantation to immunoprivileged sites. In Pancreatic Islet Transplantation, 1994, Ed., W.L, Chick and R.R Lanza, Vol. 2: pp. 75-86.
51. T.S. Griffith, T. Brunner, S.M. Fletcher, D.R. Green and T.A. Ferguson. Fas ligand-induced apoptosis as a mechanism of immune privilege Science, 1995, 270: 1189-1192.
52. P.M. Stuart, T.S. Griffith, N. Usui, J. Pepose, X. Yu and T.A. Ferguson. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. Journal of Clinical Investigation, 1997, 99(3): 396-402.
53. R. Runic, C.J. Lockwood, Y. Ma, B. Dispasquale and S. Guller. Expression of Fas ligand by human cytotrophoblasts implications in placentation and fetal survival. J. Clin. Endocrinol. Metab., 1996, 91: 3119.
54. J.S. Hunt, D. Vassmer, T.A. Ferguson and L. Miller. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. Journal of Immunology, 1997, 158(9): 4122-4128.
55. M. Hahne, D. Rimoldi, M. Schroter, P. Romero, M. Schreir, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini and J. Tschopp. Melanoma cell expression of Fas (Apo-1/CD95) ligand; implications for tumor immune escape. Science, 1996, 274(5291): 1302.
56. J. O'Connell, G.C. O'Sullivan, J.K. Collins and F. Shanahan. The Fas counter-attack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 1996, 184: 1075-1082.
57. S. Strand., W.J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer and P R. Galle. Lymphocyte apoptosis induced by CD95 (APO-1, Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nature Medicine, 1996, 2: 1361-1366.
58. P.R. Walker, P. Saas and P.Y. Dietrich. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J. Immunol, 1997, 158: 4521-4524.
59. K. Shirak, N Tsuji, T. Shioda, K.J. Isselbacher and H. Takahashi, Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc. Natl. Acad. Sci. USA. 1997, 94: 6420-6425.
60. D.R. Green and C.F. Ware. Fas-ligand. privilege and peril. Proc. Natl. Acad. Sci. USA, 1997, 94: pp. 5986-5990,
61. G.A. Niehans, T. Brunner, S. Frizelle, J C. Lisotn, C.T. Salerno, D.C. Knapp, D.R. Green and R A Kratzke. Human lung carcinomas express Fas ligand. Cancer Res. 1997, 57: 1007-1012.
62. P. Saas, P.R. Walker, M Hahne, A L. Quiquerez, V. Schnuriger, G. Perrin, L French, E.G. Van Meir, N.J. Tschopp de Tribolet and P.Y Dietrich, Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? Journal of Clinical Investigation, 1997, 99(6): 1173- 1178.
63. H.T. Lau, M. Yu, A Fontana and C.J. Stoeckert, Jr. Prevention of islet allograft rejection with engineered myoblasts FasL in mice. Science, 1996, 273: 109-112.
64. G S. Korbutt, J.F. Elliott and R.V. Rajotte. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes, 1997, 46: 317-322.
65. J. Allison, H.M. Geogriou, A. Strasser and D.L. Vaux. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infilteration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA, 1997, 94(8): 3943-3947.
66. S.M. Kang, D.B. Schneider, Z. Lin, D. Hanahan, D A. Dichek, P.G. Stock and S, Baekkeskov. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Medicine, 1997, 3(7): 738-743.
67. A.V. Chervonsky, Y. Wang, F.S. Wong, I. Visintin, R.A. Flavell, C.A Janeway Jr. and L.A. Martis. The role of Fas in autoimmune diabetes. Cell, 1997, 89(I): 17-24
68. N. Itoh, A. Imagawa, T Hanafusa, M. Waguri, K. Yamamoto, H. Iwahashi, M. Moriviaki, H. Nakajima, J. Miyagawa, M. Namba, S. Makino, S. Nagata, N Kono and Y. Matsuzawa. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med., 1997, 186: 613-618.
69. K. Yamada, N. Takane-Gyotoku, X. Yuan, F. Ichikawa, C, Inada and K. Nonaka. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetiologia., 1996, 39: 1306-1312.
70. D.A. Muruve. A.G. Nicolson, R.C. Manfro, T.B. Strom, V.P. Sukhatme and T.A. Libermann. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts Hum. Gene Ther., 1997, 8: 955-963.
71. H. Yagita, K. Seino, N Kayagaki and K. Okumura. CD95 ligand in graft rejection. Nature, 1996, 379: 682-683.
72. K. Seino, N. Kayagaki, K. Okumura and H. Yagita. Antitumor effect of locally produced CD95 ligand. Nat. Med., 1997, 3: 165-170.
73. K. Seino, N. Kayagaki, K. Fukao, K. Okumura and H. Yagita. Rejection of Fas ligand-expressing grafts Transplant. Proc., 1997, 29: 1092-1093.
74. G.W. Byrne, K.R. McCurry, M.J. Marin, S.M. McClellan, J.L. Platt and J.S. Logan. Transgenic pigs expressing human CD59 and decay-accelarating factor produce an intrinsic barrier to complement-mediated damage. Transplantation. 1997,63: 149-155.